Eagle Pharmaceuticals, Inc. (EGRX)
OTC PINK OTC PINK Primary Summary
EGRX Chart
INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Eagle Pharmaceuticals, Inc. On Behalf of Shareholders
WILMINGTON, DE / ACCESSWIRE / October 22, 2024 / Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ GM:EGRX) on behalf of stockholders.
Union Square Park Capital Management's Strategic Acquisition of Eagle Pharmaceuticals Shares
On October 3, 2024, Union Square Park Capital Management, LLC (Trades, Portfolio) made a significant move in the pharmaceutical sector by acquiring 1,191,490 shares of Eagle Pharmaceuticals Inc (EGRX, Financial). This transaction marked a new holding for the firm, purchased at a price of $1.99 per share.
Eagle Pharmaceuticals, Inc. (EGRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Eagle Pharmaceuticals, Inc. ever had a stock split?
Eagle Pharmaceuticals, Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Michael Graves CEO | OTC PINK Exchange | 269796108 CUSIP |
| US Country | 134 Employees | - Last Dividend | - Last Split | 12 Feb 2014 IPO Date |
Overview
Eagle Pharmaceuticals, Inc. is a pioneering pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of diseases affecting the central nervous system, metabolic critical care, and oncology. Founded in 2007 and based in Woodcliff Lake, New Jersey, the company strives to address complex challenges in healthcare with its diverse pipeline of product candidates and commercial products. Through its strategic collaborations and license agreements, Eagle Pharmaceuticals aims to expand its portfolio and improve patient outcomes in the United States and beyond.
Products and Services
- Ryanodex: A treatment for malignant hyperthermia, a life-threatening condition typically triggered by certain anesthesia drugs.
- Belrapzo and Bendeka: Both medications are approved for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma, offering options for patients battling these blood cancers.
- EP-4104: A dantrolene sodium formulation under development to treat organophosphate exposure, which can occur in chemical warfare and pesticide poisoning, highlighting the company's commitment to addressing critical care needs.
- PEMFEXY: A ready-to-use/dilute liquid form of pemetrexed for the treatment of non-small cell lung cancer and mesothelioma, representing advancements in chemotherapy options.
- EA-114 (fulvestrant): In development for HR+/HER- breast cancer, this product candidate denotes Eagle Pharmaceuticals' foray into targeted oncology treatments.
- Vasopressin Injection: Indicated to increase blood pressure in adults with vasodilatory shock, a critical condition often seen in intensive care units.
- License and Collaboration Agreements: The company's partnership with Combioxin, SA, focuses on CAL02, an antitoxin agent for treating severe pneumonia alongside traditional antibacterial drugs. Another notable collaboration is with AOP Orphan Pharmaceuticals GmbH for the commercialization of Landiolol, aimed at reducing ventricular rate in patients with arrhythmias such as supraventricular tachycardia. Furthermore, its strategic collaboration with Tyme Technologies, Inc. is dedicated to the development of SM-88 for treating breast cancer (HR+/HER2-) and high-risk metastatic sarcomas.
